Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.47 |
| ▸ | NPY1R | P25929 | 6/20 | 0.47 |
| ▸ | NPY2R | P49146 | 5/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958905 | 0.88 | NPY4R (0.50) | NPY4RNPY1RNPY2RNPY5RGRIA1 | |
| SCHEMBL31606492 | 0.87 | NPY4R (0.57) | NPY4RNPY1RNPY2RNPY5RGRIA1 | |
| SCHEMBL30918352 | 0.84 | NPY1R (0.52) | NPY4RNPY1RNPY2ROPRM1OPRD1 | |
| SCHEMBL30918316 | 0.81 | ACE (0.47) | — | |
| SCHEMBL30121427 | 0.81 | HDAC3 (0.47) | OPRM1 | |
| SCHEMBL30918335 | 0.79 | PTPN1 (0.42) | — | |
| SCHEMBL30350532 | 0.79 | LTA4H (0.47) | — | |
| SCHEMBL27433907 | 0.78 | CA1 (0.42) | NPY4RNPY1R | |
| SCHEMBL27389363 | 0.78 | CA1 (0.42) | NPY4RNPY1R | |
| SCHEMBL30885623 | 0.78 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RGRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| WO-2024110477-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | WO | claimed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | NPY4R 433/4885NPY1R 680/4885NPY2R 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.